iX Biopharma Ltd. (SGX:42C)

Singapore · Delayed Price · Currency is SGD

0.4650

+0.0100 (2.20%)

At close: Oct 28, 2026

Market Cap	508.39M +350.4%
Revenue (ttm)	6.85M -11.8%
Net Income	-7.99M
EPS	-0.01
Shares Out	1.09B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,258,800
Open	0.4600
Previous Close	0.4550
Day's Range	0.4600 - 0.4750
52-Week Range	0.1100 - 0.6250
Beta	1.01
Analysts	Strong Buy
Price Target	1.09 (+133.33%)
Est. Earnings	Nov 10, 2026

About iX Biopharma

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, Australia and internationally. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, insomnia and other conditions.... [Read more]

Industry Pharmaceutical Preparations

Founded 2004

Employees 37

Stock Exchange Singapore Exchange - Catalist

Ticker Symbol 42C

Full Company Profile

Financial Performance

In fiscal year 2026, iX Biopharma's revenue was 6.85 million, a decrease of -11.77% compared to the previous year's 7.77 million. Losses were -7.99 million, -21.18% less than in 2025.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 42C stock is "Strong Buy." The 12-month stock price target is $1.09, which is an increase of 133.33% from the latest price.

Price Target

$1.09

(133.33% upside)

Analyst Consensus: Strong Buy

Stock Forecasts